Member Area

Farmavita.Net - Pharmaceutical Licensing Network

Wednesday
Mar 10th
Home
Innovative Medicine Demand
Novel materials for lip products

Lips by ORTIZ054

Seeking: Novel new sensations and materials for lip products

A kiss may be just a kiss, but we're looking for unique materials to add to lip products for new lip sensations and
experiences (such as cooling, warming, numbing, tingling and flavors), solutions that can impart prolonged sensate
experiences, and solutions that can impart not-yet-known sensations.

Innovative Medicines Offer
Victory Pharmaceuticals - Late Stage Development Program in Pain Management

Development-stage pain products

The Company seeks to divest its development-stage pain products MGX-001 (extended release morphine combined with an atypical stimulant) and MGX-002 (a follow-on opioid combined with an atypical stimulant). These products are expected to significantly reduce commonly-experienced side effects versus existing opiate therapies. 
 
Generic Medicine Demand
Cephalexin syrups and Omeprazole 20mg caps

Cephalexin syrups and Omeprazole

Looking for a finished producer of Cephelexin syrups and Omeprazole 20mg x10 caps with EU dossier and current EU registartion in at least 2 EU countries for export.

Generic Medicines - Offer
Cefdinir Member of Farmavita.Net offers dossiers and supply of Cefdinir, oral suspension, 125 mg/5ml. The dossier in China is ready.

The EU CTD dossier is in development.

 
OTC / Nutraceutical Demand
N-acetylcysteine

N-acetylcysteine 1200 mg effervescent tablets

Reference Product:

Name of the product: Fluimucil 600

Name of the company: Zambon Spa

Patent expiry date: N/A

Dossier:

Language: English

Format: EU CTD

API/Technology Demand
Fermentation Technologies

prilika.jpg

Bacteria strains and fermentation technologies

Farmavita.Net member is seeking bacteria strains and fermentation technologies to produce the following products Lycopene, Chlortetracycline and Acetylisovaleryltylosin.

 
Open Innovation
McKinesey Quarterly

Using knowledge brokering to improve business processes

Over the past decade, open innovation has begun transforming the way global companies develop new products, as executives increasingly recognize the benefits of exposing internal R&D to outside ideas. Now, some organizations are going even further by applying open-source thinking to improve a range of core business processes. Aided by rapidly changing technology, these leaders are looking outside the gates to develop faster and better solutions to a variety of strategic, operational, and organizational problems.

Download free 9 pages report at our Download Section.

Life Science Article
Calotropis procera

calotropis_procera_by_manuel_m._ramos.jpg

ANTI-DIARRHEAL ACTIVITY OF ETHANOLIC EXTRACT OF CALOTROPIS PROCERA R. Br. ROOTS

Calotropis procera R. Br. (Asclepidaceae) is a shrub which widely distribute in the world. The plant is used in the treatment of many disease and disorder both in humans and veterinary application. The present work was undertaken to investigate the anti-diarrhoeal activity of ethanolic extract of root (200 mg/kg BW) of Calotropis procera against castor oil induced diarrhoea in experimental animal and was found to be significant results.

The whole 6 pages article is available for download at Downloads section of Farmavita.Net.

 
Events
PharmaBrand

pharmabrand2010_150x150.gif

PharmaBrand Summit 2010

21-23 June 2010, Le Méridien Beach Plaza, Monte-Carlo, Monaco

The PharmaBrand Europe Summit 2010 will bring together senior-level executives from Europe's largest organisations with a select and diversified group of leading edge Solution Providers. Do not miss this opportunity to network with your peers and form new alliances. Get a head start on your competition and start building relationships today.

Market Report
Rheumatoid Arthritis

datamonitor_logo.gif

Disease Modification in Rheumatoid Arthritis - Anti-TNFs defend first-line biologic position despite competition

Datamonitor forecasts that total sales for the seven major rheumatoid arthritis markets will grow from $7 billion in 2007 to over $12 billion in 2017. The sustained uptake of anti-TNFs combined with the launch of several new biologic products will drive growth in the short-and mid-term. However, biosimilar entry will cause a small contraction in market value at the end of the forecast period.

 
Advertisement
  • Networking Tips & Tricks

    Monitoring news at Farmavita.Net

    You can easily monitor all new articles published  at Farmavita.Net . Click on the RSS button and bookmark the main  RSS feed of Farmavita.Net.  RSS button is located in URL field of your browser and also at the lower right side of every Farmavita.Net page

     
  • Latest Published
 

Featured Video

More videos ...

3D Content Cloud

Featured Partners

farmavita_research-store.gif
top-20-cancer-therapy-brand.jpg
generics-growth-strategies2.gif
sfe_eu10_150x150_v2.gif 
mddexeceu10_150x150_v1.gif
discovery2010_150x150.gif
150x150_salesonco-master.gif
pharma_omaeu10_150x150_v2.gif
risksharingnextlevel.gif 
arriello-150x150.gif 
150x150_ceepr3_master.gif 
pharmabrand2010_150x150.gif
 

Login to Farmavita.Net

membership is FREE

Follow us on:

bpe_oglas.gif




Join our LinkedIn Group

BabelFish Translator




Click Flag for Translation

Who's Online

Farmavita.Net RSS News


Products

Click to Products

JobLine

Click here ...Post a Job for Free

Reports

Click to Reports

Events

Click to Events

CRAMS

Click to CRAMS